Axcelead Drug Discovery Partners (ADDP) is a Japan-based global provider of drug discovery solutions, established in 2017 as a spin-out from Takeda Pharmaceuticals.

Our Drug Discovery Service offers a fully integrated, end-to-end approach, seamlessly connects all functions to advance drug discovery programs from target validation to IND enabling studies in wide-range therapeutic areas, including neuroscience, oncology, cardiovascular, metabolic diseases, immunology & inflammation, and musculoskeletal disorders.

Leveraging legacy data from over 1,000 research projects inherited from Takeda—including hit and lead compounds as well as extensive biological datasets— we help clients accelerate progress and achieve success with their drug discovery programs.

In addition to Drug Discovery service, each of our core technology platforms is also available as a standalone service, allowing clients to access specialized capabilities as needed:

• Hit identification through high-throughput screening using our proprietary compound library
• Proprietary in silico design tools supporting medicinal chemistry design and optimization
• Validated in vivo and in vitro pharmacology evaluations delivering translational insights
• Comprehensive DMPK, safety assessment, and bioanalysis capabilities
• Expertise across multiple modalities, including small molecules, peptides, oligonucleotides, mRNA-targeted therapies, protein degraders, ADCs, and regenerative medicine.

This flexible model ensures that our clients benefit from world-class science—whether as part of a fully integrated program or by engaging individual, best-in-class services tailored to their specific needs.